Literature DB >> 2457072

In vivo and in vitro studies of microsphere pancreatic supplements.

J M Littlewood1, J Kelleher, M P Walters, A W Johnson.   

Abstract

Over the past 5 years, the Leeds Regional Cystic Fibrosis (CF) Unit has provided comprehensive annual assessments of CF patients that include dietary assessments and fat absorption studies. Enteric-coated microsphere pancreatic enzyme preparations (microsphere preparations) were compared to conventional enzymes as therapeutic agents for these patients. Presently in the U.K., two microsphere preparations are licensed for use and a further two products are likely to receive licenses in the near future. The success of these preparations is dependent on the ability of the microsphere coating to resist dissolution until the pH exceeds approximately 5.5 and thus prevent inactivation of lipase in the acid environment of the stomach. A study comparing Pancrex V Forte, a conventional enzyme preparation, to three microsphere preparations, Pancrease, Creon, and pancreatin Merck, confirmed the superiority of Pancrease and Creon over Pancrex V Forte and pancreatin Merck with regard to control of symptoms, and nitrogen and fat absorption. Because of differences in the physical characteristics of various microsphere preparations, the dissolution rates of Pancrease, Creon, and pancreatin Merck were compared in vitro. In aqueous buffers, striking differences among the preparations were seen at pH 5.5; whereas only 25% of available lipase was released from Creon, both Pancrease and pancreatin Merck show almost complete dissolution at this pH. Only at pH 6.5 and above do all three preparations show complete dissolution. In duodenal juice, as in aqueous buffers, lipase release from Creon takes place at a lower rate than with the other two preparations until pH 6.0 or higher is attained.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457072     DOI: 10.1097/00005176-198811001-00006

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  9 in total

Review 1.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 2.  Gastrointestinal complications in cystic fibrosis.

Authors:  J M Littlewood
Journal:  J R Soc Med       Date:  1992       Impact factor: 5.344

3.  In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.

Authors:  Robert J Kuhn; Sabine Eyting; Friederike Henniges; Andreas Potthoff
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

Review 4.  Abdominal pain in cystic fibrosis.

Authors:  J M Littlewood
Journal:  J R Soc Med       Date:  1995       Impact factor: 5.344

5.  Gastric transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin microsphere preparation in patients with chronic pancreatitis.

Authors:  M J Bruno; J J Borm; F J Hoek; B Delzenne; A F Hofmann; J J de Goeij; E A van Royen; D J van Leeuwen; G N Tytgat
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

Review 6.  Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.

Authors:  Tony Trang; Johanna Chan; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.

Authors:  H G Heijerman; C B Lamers; W Bakker; J H Dijkman
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

Review 8.  Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines.

Authors:  Mary E Phillips; Andrew D Hopper; John S Leeds; Keith J Roberts; Laura McGeeney; Sinead N Duggan; Rajesh Kumar
Journal:  BMJ Open Gastroenterol       Date:  2021-06

9.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.